WPI: WATSON PHARMACEUTICALS INC Profile

Ticker

Advertisement

Choose a Broker

Dynamic view of the market

U.S. Markets open in 27 hrs, 54 mins

Symbol	Value	Change	Percentage Change
DJIA	11,288.54	73.03	0.65%
NASDAQ	2,245.38	-6.08	-0.27%
S&P 500	1,262.90	1.38	0.11%

WATSON PHARMACEUTICALS INC

WPI

Stock price

27.25 0.08 0.29%

as of 01:06 PM EDT on 07/03/2008 in USD (NYSE Delay: 20 mins.)
Extended Hours

— — —

Analyst Consensus

Hold
Analyst Consensus

Strong Buy

Buy

Hold

Sell

Strong Sell
- Add to Portfolio
- Add to Alerts
Discuss: WPI

Insightful information about industries, companies, and the people who lead them.

Learn More.

2007 Sales	2007 Sales Growth	2007 Net Income	2007 Employees
$2,496,600,000	26.1%	$141,000,000	56,400

Key Executives: WPI

Name	Title	Officer Since
Paul M. Bisaro	CEO	9/4/07
Mark W. Durand	CFO	-
Thomas R. Giordano	Chief Information Officer	-
David A. Buchen	General Counsel	-
Thomas R. Russillo	Executive VP	-
Edward F. Heimers, Jr.	Executive VP	-
R. Todd Joyce	Vice President	-
Dr. Gordon Munro, Ph.D.	Divisional Senior VP	-

View All Key Executives

Paul M. Bisaro, age 47, was appointed as our President and Chief Executive Officer and to our Board of Directors effective September 4, 2007. Prior to joining us, Mr. Bisaro was President and Chief Operating Officer of Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company, from 1999 to 2007. Between 1992 and 1999, Mr. Bisaro served as General Counsel of Barr and from 1997 to 1999 served in various additional capacities including... View Full Profile

Paul M. Bisaro

Thomas R. Russillo, age 64, was appointed Executive Vice President and President of the Generics Division on September 5, 2006. Prior to joining Watson, Mr. Russillo served as a consultant to the Company from February to November, 2006, in connection with the Company's integration planning related to the acquisition of Andrx Corporation. From January 2005 until September 1, 2006 Mr. Russillo served as a consultant to various clients in the... View Full Profile

Thomas R. Russillo

Mark W. Durand, age 48, was appointed Senior Vice President, Chief Financial Officer effective November 26, 2007. Prior to joining Watson, Mr. Durand served as Chief Financial Officer and Senior Vice President, Finance and Business Development at Teva North America ("Teva NA"). Prior to joining Teva NA, he held a number of positions of increasing responsibility at Bristol-Myers Squibb from 1987 to 2004, including Vice President -Finance and... View Full Profile

Mark W. Durand

Gordon Munro, Ph.D, age 60, has served as our Senior Vice President, Quality Assurance since June 2004. Prior to joining Watson, Dr. Munro was the Director of Inspection and Enforcement, at the United Kingdom Medicines and Healthcare Products Regulatory Agency from 1997 to 2004, and from 2002 to 2004, he was also Acting Head of Medicines. From 1970 to 1997, he held various positions, including the Director of Quality and Compliance at... View Full Profile

Dr. Gordon Munro, Ph.D.

R. Todd Joyce, who has been serving the Company as interim principal financial officer since October 2006, will continue to do so until November 26, 2007. Mr. Joyce will continue as our Vice President, Corporate Controller thereafter.... View Full Profile

R. Todd Joyce

Edward F. Heimers, age 61, has served as Executive Vice President and President of the Brand Division since May 2005. Prior to joining Watson, Mr. Heimers was Senior Vice President, Marketing for Innovex, a contract sales organization and a division of Quintiles Transnational Corp. from 2000 to 2005. Prior to joining Innovex, he was Senior Vice President, Sales for Novartis Pharmaceuticals Corporation from 1996 to 1999. From 1987 to 1996, Mr.... View Full Profile

Edward F. Heimers, Jr.

Albert Paonessa, age 47, joined Watson as our Executive Vice President, Chief Operating Officer of Anda, our Distribution company following our acquisition of Andrx. Mr. Paonessa was appointed Anda Executive Vice President and Chief Operating Officer in August 2005 and had been with Anda since Andrx acquired VIP in March 2000. From March 2000 through January 2002, Mr. Paonessa was Vice President, Operations of VIP. In January 2002, he became Vice... View Full Profile

Albert Paonessa, III

Thomas R. Giordano, age 57, was appointed Senior Vice President, Chief Information Officer of Watson on December 11, 2006. Mr. Giordano joined Watson following the Company's acquisition of Andrx, where he served as Senior Vice President, Chief Information Officer and Chief Project Management Officer since 2002. Prior to joining Andrx, he was Senior Vice President and Global Chief Information Officer for Burger King Corporation, a subsidiary of... View Full Profile

Thomas R. Giordano

Fred G. Weiss, age 65, has been the managing director of FGW Associates, Inc., a consulting firm, since 1997. Mr. Weiss served as Vice President, Planning, Investment and Development of Warner-Lambert from 1983 to 1996 and prior to that served as Vice President and Treasurer of Warner-Lambert from 1979 to 1983, where he was involved in both strategic planning and corporate development. Mr. Weiss is also an Independent Vice-Chairman of the Board... View Full Profile

Fred G. Weiss

Catherine M. Klema, age 49, has been our director since March 2004. Ms. Klema is currently President of Nettleton Advisors LLC, a consulting firm established by Ms. Klema in 2001. Ms. Klema served as Managing Director, Healthcare Investment Banking, at SG Cowen Securities from 1997 to 2001. While at SG Cowen, Ms. Klema had advised us on investment banking matters. Ms. Klema also served as Managing Director, Healthcare Investment Banking, at... View Full Profile

Catherine M. Klema

Mr. Turner, age 61, has been a member of the Company"s Board since 1997. From 2003 until his appointment to the position of Chairman, he served as the chairman of the Company"s nominating and corporate governance committee, and from 1998 until his appointment to the position of Chairman, he served as a member of the Company"s audit committee. He is Chairman of the Board of EnduraCare Therapy Management, Inc., a provider of rehabilitation and... View Full Profile

Andrew L. Turner

Albert F. Hummel, age 63, has been our director since March 1986, except for a period from July 1991 to October 1991. Mr. Hummel has been President of Pentech Pharmaceuticals, Inc., a development stage pharmaceutical company, since July 1998. Since November 2005, Mr. Hummel has been a director for Obagi Medical Products, Inc., a specialty pharmaceutical company focused on the aesthetic and therapeutic skin health markets. Additionally, Mr. Hummel... View Full Profile

Albert F. Hummel

Albert F. Hummel, age 63, has been our director since March 1986, except for a period from July 1991 to October 1991. Mr. Hummel has been President of Pentech Pharmaceuticals, Inc., a development stage pharmaceutical company, since July 1998. Since November 2005, Mr. Hummel has been a director for Obagi Medical Products, Inc., a specialty pharmaceutical company focused on the aesthetic and therapeutic skin health markets. Additionally, Mr. Hummel... View Full Profile

Allen Chao, Ph.D.

Charles D. Ebert, Ph.D., age 54, has served as our Senior Vice President, Research and Development since May 2000. He served as our Senior Vice President, Proprietary Research and Development from June 1999 to May 2000. Before joining Watson, Dr. Ebert served TheraTech, Inc. as Vice President, Research and Development from 1987 to 1992 and as Senior Vice President, Research and Development since 1992. Dr. Ebert serves on the Board of Directors of... View Full Profile

Dr. Charles D. Ebert, Ph.D.

David A. Buchen, age 43, has served as Senior Vice President, General Counsel and Secretary since November 2002. From November 2000 to November 2002, Mr. Buchen served as Vice President and Associate General Counsel. From February 2000 to November 2000, he served as Vice President and Senior Corporate Counsel. From November 1998 to February 2000, he served as Senior Corporate Counsel and as Corporate Counsel. He also served as Assistant Secretary... View Full Profile

David A. Buchen

David C. Hsia, Ph.D., age 63, has served as our Senior Vice President, Scientific Affairs since May 1995 and has been a Vice President of Watson since 1985. Dr. Hsia is also co-founder of Watson. He has been involved in the development of pharmaceutical formulations for oral contraceptives, sustained-release products and novel dosage forms for over 20 years. Dr. Hsia received a Ph.D. in Industrial and Physical Pharmacy from Purdue University in... View Full Profile

Dr. David C. Hsia, Ph.D.

Jack Michelson, age 73, has been our director since February 2002 and was our consultant from February 2001 to June 2003. Mr. Michelson served as an officer of G.D. Searle & Co., a pharmaceutical company, for twenty-four years, of which Mr. Michelson was Corporate Vice President and President, Technical Operations from 1993 to 2001; Senior Vice President of Technical Operations from 1981 to 1993; and Vice President of Production and Engineering... View Full Profile

Jack Michelson

Michael J. Fedida, age 61, a registered pharmacist, has served for the past twenty-six years as an officer and director of several retail pharmacies wholly or partially owned by him, including J&J Saint Michael's Pharmacy from 2005 to present; J&J Pharmacy and Classic Pharmacy from 1987 to present; Perfect Pharmacy from 1980 to 2000; and Phoster Pharmacy from 1985 to 2000. Mr. Fedida served on the Board of Directors of Circa Pharmaceuticals,... View Full Profile

Michael J. Fedida

Michel J. Feldman, age 66, is a member of the law firm of Seyfarth Shaw LLP, where he has practiced since October 2003. Previously, Mr. Feldman was a member of the law firm of D'Ancona & Pflaum LLC, where he practiced from June 1991 to October 2003. Effective October 2003, D'Ancona & Pflaum LLC merged with Seyfarth Shaw LLP. From time to time in the past, Seyfarth Shaw LLP provided legal services to us. Mr. Feldman also served as our Secretary... View Full Profile

Michel J. Feldman

Susan Skara, age 57, has served as our Senior Vice President, Human Resources since November 2002. Ms. Skara joined Watson in March 1999 as Vice President, Human Resources, a position she held until her promotion to Senior Vice President in November 2002. Prior to joining Watson, Ms. Skara worked for Apria Healthcare and last held the position of Senior Vice President of Human Resources from November 1996 to June 1998. Ms. Skara received a B.A.... View Full Profile

Susan Skara

Ronald R. Taylor, age 60, has been President of Tamarack Bay, LLC, a private consulting firm, since 2001. Mr. Taylor has been a director of Red Lion Hotels Corporation, a hotel operating company, since 1998 and a director of ResMed Inc., a medical device manufacturer, since 2005. Mr. Taylor was a limited partner of Enterprise Partners Venture Capital, a venture capital firm, from April 2001 until September 2002, and was formerly a general partner... View Full Profile

Ronald R. Taylor

Francois A. Menard, Ph.D, age 48, was appointed Senior Vice President, Generics Research and Development of Watson on February 8, 2008. Prior to joining Watson, Dr. Menard served as Vice President Product Development at Sandoz from 2004 to 2008. Prior to Sandoz, Dr. Menard was Vice President, Research and Development at Ivax Corporation during 2004 and before Ivax Corporation held a number of product development positions of increasing... View Full Profile

Dr. Francois A. Menard, Ph.D

Top Competitors: WPI

View Detailed Competitors Chart

Insider Trends: WPI
Sentiment for WPI is NEGATIVE
- 0M
- 2M
- 4M
- 6M
- Market Value of Insider Sales
- Market Value of Insider Purchases
Total dollar value of all insider purchases and sales over 12 months
View All Insider Sentiment

Insider Transactions: WPI

Date	Name	Shares	Transaction Type	Market Value
05/15/08	HSIA DAVID C	100,000	Sale	$2.86 M
05/09/08	FEDIDA MICHAEL J	5,000	Award of Stock Options	$0.00
05/09/08	WEISS FRED G	5,000	Award of Stock Options	$0.00

View All Insider Activity

Ownership Breakdown : WPI

Large Block Holder Type	Number
Institutions	360.00
Mutual Fund	774.00
Other Major	14.00

Full Details

Indices : WPI

Symbol	Name	Last Trade	Change
$RUI.X	Russell 1000 Index	690.92	-0.56 -0.08%
$INX	S&P 500 Index	—	——%

View all Indices that include WPI

Short Interest Volume: WPI

Data as of 6/10/08

Current Short Interest Shares	1.10 B
Current Short Interest Ratio	5.80
Float	98.19 M

Short Interest as % of Float	4.80
Average Daily Volume	830,000.00
Outstanding Shares	104.44 M

Full Details

SEC Filings: WPI

Accepted Date	Description
06/30/2008	SEC Filing: Annual Rpt Employee Plans
06/30/2008	SEC Filing: Annual Rpt Employee Plans
05/16/2008	SEC Filing: Insider Buy/Sell

View all SEC Filings

Get Profile Details for:

- Help & Feedback

Market Movers

Related Resources

My Portfolios

AOL Real-Time Streaming Quotes

WATSON PHARMACEUTICALS INC

WPI

Stock price

27.25 0.08 0.29%

as of 01:06 PM EDT on 07/03/2008 in USD (NYSE Delay: 20 mins.)
Analyst Consensus
- Strong Buy
- Buy
- Hold
- Sell
- Strong Sell
- Add to Portfolio
- Add to Alerts
Discuss: WPI

Quote Search Search the Web Search

Live Updates:

Ticker

Dynamic view of the market

WATSON PHARMACEUTICALS INC

WPI

Stock price

Extended Hours

Analyst Consensus

WATSON PHARMACEUTICALS INC Profile

Key Executives: WPI

Top Competitors: WPI

Insider Trends: WPI

Insider Transactions: WPI

Ownership Breakdown : WPI

Indices : WPI

Short Interest Volume: WPI

SEC Filings: WPI

Quote Details

Classic Chart

Advanced Chart BETA

Real-Time Headlines

Message Boards

Profile

Earnings Analysis

Event Calendar

Financials

Market Movers

Related Resources

WATSON PHARMACEUTICALS INC

WPI

Stock price

Analyst Consensus

More in Money & Finance